Gene Green: “Robust competition in the prescription drug market between innovative drugs and generic drugs is crucial.”

Neither these bills nor the Committee's other efforts have gone far enough to address many of the underlying challenges facing this sector.

I hope we all agree on the importance of 340B and the need to stretch scarce federal resources as far as possible to reach more eligible patients and provide more comprehensive services.

It is the hope of our committee and Congress that these investments are being put towards finding a cure for many of our nation's biggest medical priorities.

I would like to thank Dr. Rucker for testifying today on the Office of National Coordinator's work to implement the 21st Century Cures Act.